SRC and cancer: Although molecularly targeted drugs, particularly kinase inhibitors, are changing the landscape of cancer therapy, the build-up of resistance to FDA-approved kinase inhibitors is posing a severe challenge [11,12], and c-Src plays a critical role in mediating drug resistance.